US biotech 23andMe hits new lows as Sequoia Capital sells down stake

US biotech 23andMe hits new lows as Sequoia Capital sells down stake

FT.com

Published

Former investors and board members reduce holdings in the once much-hyped genetics-testing group

Full Article